Updating results

57 results for dermatology Sort: Relevance | Date

Melanoma: assessment and management (NG14)

This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

NICE guideline Published July 2015

Psoriasis (QS40)

This quality standard covers assessing and managing psoriasis in adults, young people and children. It describes high-quality care in priority areas for improvement.

Quality standard Published August 2013

Psoriasis

Everything NICE has said on psoriasis in an interactive flowchart

NICE Pathway Published October 2011 Last updated June 2018

Atopic eczema in under 12s: diagnosis and management (CG57)

This guideline covers diagnosing and managing atopic eczema in children under 12. It aims to improve care for children with atopic eczema by making detailed recommendations on treatment and specialist referral. The guideline also explains how healthcare professionals should assess the effect eczema has on quality of life, in addition to its physical severity.

Clinical guideline Published December 2007

Psoriasis: assessment and management (CG153)

This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

Clinical guideline Published October 2012 Last updated September 2017

Eczema

Everything NICE has said on managing atopic eczema in children up to 12 years, and treating eczema in people aged 13 years and over in an interactive flowchart

NICE Pathway Published August 2012 Last updated July 2018

Tacrolimus and pimecrolimus for atopic eczema (TA82)

Evidence-based recommendations on non-steroidal tacrolimus and pimecrolimus for treating atopic eczema (atopic dermatitis)

Technology appraisal guidance Published August 2004

Risankizumab for treating moderate to severe plaque psoriasis (ID1398)

In development [GID-TA10349] Expected publication date: 21 August 2019

Technology appraisal guidance In development

Adalimumab for the treatment of adults with psoriasis (TA146)

Evidence-based recommendations on adalimumab (Humira) for the treatment of adults with plaque psoriasis

Technology appraisal guidance Published June 2008

Infliximab for the treatment of adults with psoriasis (TA134)

Evidence-based recommendations on infliximab (Remicade) for treating psoriasis in adults

Technology appraisal guidance Published January 2008

Alitretinoin for the treatment of severe chronic hand eczema (TA177)

Evidence-based recommendatrions on alitretinoin (Toctino) for treating severe chronic hand eczema in adults

Technology appraisal guidance Published August 2009

ESNM14: Actinic keratosis: ingenol mebutate gel

Summary of the evidence on ingenol mebutate gel for actinic keratosis (solar keratosis) to inform local NHS planning and decision-making

Evidence summary Published March 2013

Guselkumab for treating moderate to severe plaque psoriasis (TA521)

Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published June 2018

ES10: Hyperhidrosis: oxybutynin

Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published March 2017

Omalizumab for previously treated chronic spontaneous urticaria (TA339)

Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)

Technology appraisal guidance Published June 2015

ESUOM31: Chronic urticaria: off-label doses of cetirizine

Summary of the evidence on off-label doses of cetirizine for chronic urticaria (hives) to inform local NHS planning and decision-making

Evidence summary Published July 2014

ESNM68: Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream

Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

Evidence summary Published January 2016

ESNM43: Facial erythema of rosacea: brimonidine tartrate gel

Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making

Evidence summary Published July 2014

Food allergy in under 19s

Everything NICE has said on diagnosing and assessing food allergy in children and young people in primary care and community settings in an interactive flowchart

NICE Pathway Published December 2011 Last updated October 2018

Skin cancer (QS130)

This quality standard covers preventing, assessing, diagnosing and managing skin cancer (malignant melanoma and non-melanoma). It describes high-quality care in priority areas for improvement.

Quality standard Published September 2016

Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published April 2017

Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)

Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer

Medical technologies guidance Published July 2011

ESUOM29: Difficult-to-treat scabies: oral ivermectin

Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making

Evidence summary Published March 2014

Dupilumab for treating moderate to severe atopic dermatitis (TA534)

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults

Technology appraisal guidance Published August 2018

Brodalumab for treating moderate to severe plaque psoriasis (TA511)

Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published March 2018

Entrectinib for treating NTRK fusion-positive solid tumours ID1512

In development [GID-TA10414] Expected publication date: 01 April 2020

Technology appraisal guidance In development

Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published September 2017

ESUOM47: Infantile haemangioma: topical timolol

Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making

Evidence summary Published August 2015

ESUOM16: Hyperhidrosis: oral glycopyrronium bromide

Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published July 2013

Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)

This guideline covers recognising, assessing, diagnosing and treating obsessive-compulsive disorder and body dysmorphic disorder in adults, young people and children (aged 8 years and older). It aims to improve the diagnosis and treatment of obsessive-compulsive disorder and body dysmorphic disorder. It includes recommendations on how families and carers may be able to support people with either of these conditions, and how they can get support for themselves.

Clinical guideline Published November 2005

Apremilast for treating moderate to severe plaque psoriasis (TA419)

Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published November 2016

Frequency of application of topical corticosteroids for atopic eczema (TA81)

Evidence-based recommendations on the frequency of application of topical corticosteroids for treating atopic eczema (atopic dermatitis)

Technology appraisal guidance Published August 2004

Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

Evidence-based recommendations on ustekinumab (Stelara) for treating moderate to severe psoriasis in adults

Technology appraisal guidance Published September 2009 Last updated March 2017

Spondyloarthritis in over 16s: diagnosis and management (NG65)

This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.

NICE guideline Published February 2017 Last updated June 2017

Haematological cancers: improving outcomes (NG47)

This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.

NICE guideline Published May 2016

ESNM66: External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment

Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

Evidence summary Published December 2015

Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

Evidence-based recommendations on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Technology appraisal guidance Published June 2016

Spondyloarthritis (QS170)

This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

Quality standard Published June 2018

Sunlight exposure: risks and benefits

Everything NICE has said on how to communicate the risks and benefits of natural sunlight exposure in an interactive flowchart

NICE Pathway Published February 2016 Last updated June 2017

Obinutuzumab for untreated advanced follicular lymphoma (TA513)

Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults

Technology appraisal guidance Published March 2018

VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)

Evidence-based recommendations on VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions

Diagnostics guidance Published November 2015

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

Evidence-based recommendations on etanercept (Enbrel) infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis

Technology appraisal guidance Published August 2010

Spondyloarthritis

Everything NICE has said on diagnosing and managing spondyloarthritis in people aged 16 and over in an interactive flowchart

NICE Pathway Published February 2017 Last updated March 2019

Committee A members

University Hospital. His clinical interests are paediatric HIV and paediatric dermatology. He is also the clinical lead for paediatrics....

Published January 2019

Melanoma

Everything NICE has said assessing and managing melanoma in an interactive flowchart

NICE Pathway Published July 2015 Last updated February 2019

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for treating plaque psoriasis in children and young people

Technology appraisal guidance Published July 2017

Ustekinumab for treating active psoriatic arthritis (TA340)

Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults

Technology appraisal guidance Published June 2015 Last updated March 2017